Trial Profile

BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabrafenib (Primary) ; Trametinib (Primary)
Indications Brain metastases; Malignant melanoma
Focus Therapeutic Use
Acronyms COMBI-MB
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK; Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

07 Jun 2022 Results (n=125) of a post-hoc analysis assessing association of baseline corticosteroid treatment with outcomes presented at the 58th Annual Meeting of the American Society of Clinical Oncology
12 Feb 2021 Results of a clinical validation study assessing Circulating tumour DNA in patients with advanced melanoma from trials COMBI-d and COMBI-MB published in the Lancet Oncology
20 Feb 2018 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com